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BACKGROUND:  The  life  expectancy  of  patients  with
cystic  fibrosis  (CF)  is  largely  dependent  on  the
pulmonary  disease severity  and progress.  Malnutri-
tion  may  be  an  important  complicating  factor  in
active and chronic lung disease.
Aims: The  focus  of  this  study  was  to  investigate
several inflammatory  markers  in  pancreatic-insuffi-
cient  CF  patients  with  different  enzyme  treatment
regimens.
Methods: CF  patients  with  pancreatic  insufficiency
were examined at a time  of symptomatic  exacerba-
tion of their lung disease. Group A (n = 11) regularly
received microspheric enzymes. Group B (n = 8) were
treated  with  enzymes  during  the  hospitalization
period only and demonstrated the presence of malnu-
trition.  Inflammatory  markers  in  the  sputa  (neu-
trophil  elastase  activity,  interleukin-8  and  tumour
necrosis factor-a levels) and in the peripheral blood
(plasma  malondialdehyde  (MDA),  lymphocyte
response to  PHA, and the cell  sensitivity  to  steroid
suppression) have been investigated.
Results: During  acute  lung  exacerbation,  group  B
demonstrated reduced levels of lymphocyte prolifera-
tion. This parameter was normalized after combined
antibiotic and pancreatic enzyme therapy. Simultane-
ously,  plasma  MDA in group  B  markedly  increased
following  treatment.  For  this  group,  a  significant
positive linear association between values of plasma
MDA  and  lymphocyte  proliferation  has  been
observed. For group A, neither the same correlation
nor changes in MDA levels and lymphocyte prolifera-
tion have been found.
Conclusions: Our data indicate that acute lung exacer-
bation in malnourished CF patients may be associated
with  alteration  in  T-lymphocyte  activity.  Adequate
therapy normalizes lymphocyte function but results
in systemic oxidative stress.
Key words: Cystic fibrosis, Inflammatory response, Oxida-
tive stress, Pancreatic insufficiency
Introduction
The life expectancy of patients with cystic fibrosis (CF)
is largely dependent on the pulmonary disease severity
and progress. Abnormal function of CF transmembrane
regulator  (CFTR)  results  in  obstructive  pulmonary
process due to accumulation of thick, viscous mucus,
which  leads  to  impaired  mucociliary  clearance.1
During the first years of life, young children with CF
are colonized and develop pneumonia secondary to
Staphylococcus aureus, Haemophilus influenzae or,
less commonly, Klebsiella pneumoniae.2 The pulmo-
nary  infections  incite  an  intense  inflammatory
response characterized by  a  marked influx  of  neu-
trophils into the lung, and elevation in inflammatory
mediators such as tumour necrosis factor-a (TNF-a ),
interleukin  (IL)-1b ,  IL-6,  IL-8,  and  leukotriene  B4.3
Lung inflammation is greatly amplified after Pseudo-
monas aeruginosa infection. Colonization with the
pathogen initiates exuberant host immune response
with a 1000-fold increase in the numbers of activated
neutrophils  releasing  excessive  amounts  of  elastase
and oxidants, which may directly damage pulmonary
epithelium.4–6A consequence of the persistent inflam-
mation and repeated cycles of infection is progressive
lung damage and pulmonary fibrosis.7
The  other hallmark  CF  manifestation  is  exocrine
pancreatic  dysfunction,  resulting  in  malnutrition,
growth  failure  and  specific  nutritional  deficiencies.
These abnormalities clearly contribute to acute and
chronic lung disease. Thus, the occurrence of malnu-
trition seems to be associated with respiratory muscle
weakness,  impaired  repair  of  airway  walls  and
immune dysfunction.8–11 Among specific nutritional
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soluble  vitamins (antioxidants) and polyunsaturated
fatty acids (PUFAs).12 There are considerable clinical
implications of these deficiencies. Malabsorption of
fat-soluble  antioxidants exacerbates  systemic  oxida-
tive stress, increases free radical tissue damage and
promotes excessive inflammatory response. A num-
ber of studies have added information about the last
effect,  showing  that  unopposed  reactive  oxygen
species (ROS) may directly activate the transcription
nuclear factor-k B, which induces expression of genes
involved in inflammatory and acute phase response.13
In  addition,  increased  ROS  generation  and,  as  a
consequence, elevated fatty acid oxidation may aggra-
vate  PUFA  deficiency,  which  is  associated  with
alteration in membrane composition and impairment
of  immune  cell  activity.14 Most  patients  with  CF
achieve adequate nutrient absorption with intakes of
pancreatic  enzymes;  others,  despite  huge  doses,
remain  symptomatic.  It  seems  that  the  extent  of
compensation of abnormalities associated with pan-
creatic  insufficiency  is  individual  and  depends  on
patient genotype and dietary management.
This study aimed to compare inflammatory markers
in  pancreatic-insufficient  CF patients with  different
enzyme treatment regimens. The first patient group
regularly  received  enteric-coated  enzyme  micro-
spheres/mini-tablet preparations, and the second was
treated with enzyme supplements during the period
of hospitalization only. The patients were examined at
a  time  of  symptomatic  exacerbation  of  their  lung




Nineteen  patients  from  the  Cystic  Fibrosis  Depart-
ment  of  the  Research  Center for  Medical Genetics
(Moscow) were enrolled in the study. Cystic fibrosis
was diagnosed by increased chloride concentrations
(>60mmol/l)  in  a  sweat  test  and  typical  clinical
symptoms of the disease, and/or detection of muta-
tions in both CFTR alleles. All subjects had evidence
of pancreatic insufficiency requiring enzyme replace-
ment  therapy. The  patients  were  divided  into  two
groups depending on their previous history. Group A
(n = 11) consisted of individuals who had regularly
received  currently  recommended  lipase/protease
intake  for  each  kilogram  of  body  weight.  Eight
patients  were  treated  with  microspheric  enzymes
during the period of hospitalization only (group B).
The  reasons  for  irregular  pancreatic  enzyme  treat-
ment  were  social,  including  the  tardy  receiving  of
government  support,  infrequent  follow-up  at  the
centres, and parent’s preference. The patients were
recruited at a time of symptomatic exacerbation of
their lung  disease, defined as a marked increase of
C-reactive protein, by weight loss, anorexia, increased
cough, increased sputum production, fever with and
without  new  lung  infiltrates,  and  deterioration  of
oxygen saturation and pulmonary function. Patients
with  acute  pulmonary  exacerbation  were  treated
with  basic  therapy  (microspheric  enzymes,  multi-
vitamins,  high  colory  diet,  mucolytics)  and  anti-
biotics.  Antibacterial  treatment  depended  on  the
microbiology analysis of the sputum. In the case of P.
aerugenosa infection, cephalosporins of third genera-
tion  in  combination  with  aminoglycosids  or  cipro-
floxacin were prescribed. The study was approved by
the local ethics committee.
Information  regarding  demographic  data,  pulmo-
nary function test results (forced expiratory volume in
1sec  and  forced  vital  capacity),  nutritional  status
(assessed by the weight to height ratio (W/H)), and
respiratory secretion cultures was obtained from the
Cystic Fibrosis Department of the Research Center for
Medical  Genetics.  Results  of  pulmonary  tests  and
nutritional  status  assessment  are  expressed  as  a
percentage  of  predicted  values  for  age,  sex,  and
height.
Blood collection and sputum processing
Blood was collected in tubes with heparin (25IU/ml)
by venopuncture.
The weight of each sputum sample was calculated.
The same weight of phosphate-buffered saline with-
out Ca2+ and Mg2+ was added to the sputum sample.
The mixture placed on vortex for 10sec and then on
the  rocker  for  30min.  The  sample  was  filtered
through a 100m m filter to remove mucus. The filtrate
has been centrifuged at 400 ´ g for 10min at 4°C to
pellet the cells. Protein concentration was measured
by  Bradford’s  method.15,16 The  supernatant  was
removed, aliquoted and stored at –60°C.
Measurement of malondialdehyde
Malondialdehyde (MDA) was measured using 2-thio-
barbituric  acid.  Briefly,  50m l  plasma  are  added  to
640 m l bidistilled water followed  by the addition of
100 m l  thiobarbituric  acid  (10mg/ml)  and  60 m l  of
14% H3PO4. Samples were heated for 45min at 100°C
and cooled down, then 850 m l n-butanol were added.
After precipitate formation, probes were centrifuged
and absorbance of supernatants at 532 and 570nm
determined. The  concentration of  MDA  was  calcu-
lated using the formula:
MDA (m M) = (Ds–Dc) ´ 102.6
where Ds =  absorbance at 532nm – absorbance at
570nm (for the plasma sample), Dc = absorbance at
532nm – absorbance at 570nm (for the control), and
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coefficient,  the  length  of  the  light  path,  and  the
volume of the reaction mixture.
Inhibition of PHA-induced lymphocyte
proliferation by dexamethasone
Mononuclear  cells  were  isolated  from  heparinazed
peripheral  blood  by  Ficoll-Verographin  density  gra-
dient centrifugation. The cells were washed twice in
RPMI-1640  medium  (ICN, USA)  supplemented with
10% heat-inactivated donor horse serum, 2 ´ 10–3 M
HEPES, 2 mM L-glutamine, 2.8 ´ 10–6 M 2-mercaptoe-
thanol,  and  20 m g/ml  gentamycin.  The  cells  were
cultivated  in  flat-bottomed  96-well  plates  (Costar,
USA), and contained 5 ´ 104 cells in each well. The final
concentration  of  PHA  (Sigma,  USA)  was  5m g/ml.
Inhibition of PHA stimulation by dexametasone was
evaluated at six different concentrations within the
dose range of 10–10 to 10–6 M. Dexametasone was not
added to the control wells (they contained a culture
medium  with  or  without  PHA).  The  cells  were
incubated for 72h at 37°C in a humidified atmosphere
containing  5%  CO2.  Four  hours  before  the  end  of
cultivation,  each  well  was  pulsed  with  40kBq
[3H]-thymidine  (Isotope,  Russia).  The  cells  were
harvested with a cell harvester and counted on a liquid
scintillation counter. Triplicate wells of each concen-
tration  were  assayed  and  the  counts  per  minute
(count/min) were averaged. Percentage inhibition was
calculated by dividing the count/min in each inhibited
sample by  the count/min  in  the sample containing
PHA only, subtracting the background level (counts/
min in the wells with culture medium only) from these
values. The intensity of suppression was estimated by
probit analysis and expressed as ED50, i.e. a dose of
immunosuppressive agent at which lymphocyte pro-
liferation  was  50%  of  its  maximum.  Previously,  the
direct positive correlation between the level of PHA-
induced lymphocyte proliferation and of the inhibition
degree of such stimulation by dexamethasone (ED50)
has been shown. On the basis of this correlation, we
proposed  the  method  of  evaluation  of  individual
susceptibility to the antiproliferative effect of gluco-
corticoids  by  D h-parameter  calculation.17 D h was
calculated using the formula:
D h = Y – Y9
where Y = log ED50, Y9 = 0.447X – 4.399, and X = ln
(count/min)
Assay of human leukocyte elastase activity
The  method  is  based  on  the  ability  of  neutrophil
elastase  to  interact  with  the  specific  chromogenic
BANE (N-t-Boc-L-alanine p-nitrophenyl ester) (Reanal,
Hungary) at acidic pH, forming p-nitrophenol with a
maximum of absorbance at 347.5nm.18,19 The stand-
ard assay was performed in 0.6ml solution containing
an  aliquot  of  sputum  sample  (20–200 m l),  0.01M
BANE (20 m l) and 0.05M sodium phosphate at 24°C
and pH 6.5. Probes were assayed for absorbance at
347.5nm for 12–15min. The absorbance per minute
was  then  calculated. The  amount  of  elastase  was
calculated using the formula:
Elastase activity (U/ml) = D347.5 ´ 109/V
where D347.5 is the absorbance per minute and V is
the  volume  of  the  sputum  aliquot  added;  109  is  a
parameter that includes the extinction coefficient, the
length  of  the  light  path,  and  the  volume  of  the
reaction mixture. Under the specified conditions, one
unit  of  human  neutrophil elastase activity was that
amount  that  hydrolyzed  1nM  BANE  per  minute.
Finally, the value of neutrophil elastase activity was
normalized to the protein content in each sample of
the sputum extract.
Cytokine assays
TNF-a activity was determined by the method of Ruff
and Gifford20 with some modifications. Briefly, L929
cells were seeded at a density of 3 ´ 104 cells per well
in 96-well plates in 100m l medium 199 to which 10%
heat-inactivated calf  bovine  serum  and  gentamycin
had been added. Plates were incubated at 37°C in a
humidified atmosphere containing 5% CO2 until the
monolayer formation. After the culture medium elim-
ination, twofold serial dilution of the samples (100 m l
each dilution) and 100 m l fresh culture medium with
20 m g/ml  actinomycin  D  (Serva,  Germany)  were
added, and  further  incubated  for  18h  at  the  same
conditions.  Supernatants  were  then  removed  and
cells stained with 0.2%  crystal violet (Sigma,  USA).
After washing and drying, plates were finally read at
595nm  on  a Titertek  Multiskan  microElisa  reader.
Human  recombinant TNF-a (Institute  of  Bioorganic
Chemistry,  Moscow,  Russia)  was  used  as  internal
standard. For  the  comparison  of  experimental  and
calibrating  curves,  the  probit-analysis  method  was
used. TNF-a content in the samples was expressed in
picograms per millilitre and normalized to the protein
content in each sputum sample.
IL-8 was determined in the sputum samples using a
commercially  available  enzyme-linked  immunosor-
bent  assay  (Proteinovyi  Kontur,  St.  Petersburg,
Russia)
Statistical analysis
Statistical  analysis  was  performed  using  non-para-
metric Wilcoxon tests. Correlation between  plasma
MDA  and  lymphocyte  proliferation  was  analyzed
using Spearman rank correlation.
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Characteristic of patients
The patient group characteristics are summarized in
Table 1. Of the patients, 14 (74%) were chronically
colonized with  P. aeruginosa. Assessment of  nutri-
tional status revealed that patients irregularly treated
with  pancreatic  enzymes  showed  lower W/H  then
those  who  were  regularly  received  microspheric
enzyme intakes (75.2 ± 2.0 and 87.5 ± 2.7, respec-
tively; P = 0.016). Thus, W/H values between 70 and
82%  were  found  in  six  children  belonging  to  the
group B (n = 8). In the same time, only four out of 11
patients from group A demonstrated the presence of
malnutrition defined as W/H < 85%. With regard to
age  and  lung  function  failure,  there  were  no  sig-
nificant differences between the patient groups.
Plasma MDA levels in CF patients
Figure 1 displays plasma MDA concentrations in CF
patients during an exacerbation and after antibiotic
treatment.  For  group A,  plasma  MDA  levels  during
acute lung exacerbation showed a median of 2.05 m M
(mean  value,  2.02  ±  0.06 m M).  In  group  B,  MDA
concentrations with median 1.89 m M were situated in
similar  range  (2.02  ±  0.13 m M;  P =  1).  Antibiotic
administration  moderately  decreased  plasma  MDA
values  in  group  A  but  this  change  did  not  reach
significance (1.94 ± 0.10 m M; P = 0.62). In the same
time,  plasma  MDA  levels  in  group  B  significantly
increased with treatment and reached a median value
of 2.51 m M (2.75 ± 0.40; P = 0.021), which is much
higher than that seen in group A at exacerbation and
recovery (both P < 0.017).
Proliferative response to PHA and lymphocyte
susceptibility to glucocorticoids
During  acute  lung  exacerbation,  the  patients  from
group  A  had  greater  levels  of  T-cell  proliferative
response than CF subjects belonging to group B (P =
0.026;  Fig.  2). The  values  expressed  as  uptake  of
3[H]-thymidine  were  82871  ±  10924  counts/min
(group A) and 52255 ± 5785 counts/min (group B).
Antibiotic  administration did  not induce  any altera-
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Table 1. Characteristics of the study subjects
Group A (n = 11) Group B (n = 8) P value
Age (years) 12.8 ± 0.6 10.5 ± 1.2 0.25
FEV1 (% pred.) 56.7 ± 6.2 59.9 ± 12.5 0.83
FVC (% pred.) 69.9 ± 4.6 74.5 ± 8.6 0.65
W/H (%) 87.5 ± 2.7 75.2 ± 2.0 0.02
Group A, Regular treatment with pancreatic enzyme replacement; group B, treatment with pancreatic enzyme
replacement during period of hospitalization only. FEV1, forced expiratory volume in 1sec; FVC, forced vital
capacity; W/H, weight to height ratio; % pred., percentage of predicted values. Differences between patient
groups were analyzed using the unpaired Wilcoxon test. Data are presented as mean ± SEM.
FIG. 1. Plasma malondialdehyde (MDA) levels in pancreatic
insufficient cystic fibrosis patients before and after antibiotic
treatment. Results are expressed as  mean ±  SEM. A two-
sample Wilcoxon test was used to compare the means of
MDA  levels  in  a  separate  patient  group  before  and  after
antibiotic  treatment  (P3,4 =  0.021).  Differences  in  plasma
MDA  between  patient  groups  were  analysed  using  the
unpaired Wilcoxon test (P1,4 = 0.017; P2,4 = 0.016).
FIG.  2.  PHA-induced  T-lymphocyte  proliferation  in  cystic
fibrosis patients during lung exacerbation treatment. Results
are given as count per minute. Median values are indicated
by the lines. Each dot represents one patient. Data reported
were compared by Wilcoxon test (P1,3 = 0.026).tion  in T-cell  proliferative  response  in  the  patients
regularly  treated  with  pancreatic  enzyme  intakes
(84073 ± 14890 counts/min; P = 0.95). At the same
time, T-cell proliferative response to PHA in group B,
lower at exacerbation, was increased during recovery
(79715 ± 14890 counts/min), but this change did not
reach significance (P = 0.07). However, the levels of
T-cell proliferation in the patients from groups A and B
became  statistically  equivalent  (P =  0.85).  A  sig-
nificant positive linear association between values of
plasma  MDA  and T-lymphocyte  proliferation  in  the
patients from group B has been observed (Fig. 3). For
group A, the same correlation has not been found.
To  evaluate  individual  susceptibility  to  glucocor-
ticoids, the D h parameters were calculated as descri-
bed in ‘Materials and methods’. Patients were classi-
fied  as  steroid  resistant  if  their  D h parameters
increased > 0 and as steroid sensitive if this parameter
failed to increase > 0 (Fig. 4). During the acute lung
exacerbation,  peripheral  blood  lymphocytes  of
patients from group B demonstrated the resistance to
antiproliferative action of dexametasone (D h = 0.48 ±
0.15).  In contrast, the  patients from  group A  were
relatively steroid sensitive (D h = –0.05 ± 0.14). There
were statistically significant differences between the
groups (P = 0.035). Following treatment, both patient
groups showed the switch from steroid resistance to
steroid sensitivity.  However,  patients  from  group  B
demonstrated  a  statistically  significant  increase  in
lymphocyte sensitivity to steroid suppression (D h =
–0.24 ± 0.18; P < 0.03). For group A, the change in D h
values did not reach significance (D h = –0.37 ± 0.20;
P = 0.07).
In situ inflammatory markers
During  acute  lung  exacerbation,  elevated  elastase
activity,  high  amounts  of  IL-8  and  TNF-a ,  and
increased protein concentrations have been observed
in the sputum samples from patients of both groups
(Table 2). However, in the regularly treated patients,
all indexes of inflammation were clearly higher than
those in children who irregularly received pancreatic
enzyme  supplement.  Antibiotic  treatment  failed  to
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Table 2. In situ inflammatory markers in patients with cystic fibrosis during an exacerbation and after antibiotic treatment














Elastase activity (U/mg protein) 28.5 ± 5.7 45.0 ± 10.8 0.14 16.6 ± 4.1 13.2 ± 7.1* 0.61
IL-8 (ng/mg protein) 6.0 ± 1.0 5.8 ± 0.7 0.89 5.4 ± 0.9 4.0 ± 1.1 0.41
TNF-a (ng/mg protein) 2.1 ± 1.0 2.3 ± 0.9 0.89 1.2± 0.8 1.0 ± 0.7 0.83
Protein (mg/ml) 3.3 ± 0.8 3.0 ± 0.7 0.82 1.3 ± 0.3* 1.5 ± 0.6 0.75
Group A, Regular treatment with pancreatic enzyme replacement; group B, treatment with pancreatic enzyme replacement during period of
hospitalization only. Data are presented as mean ± SEM. * P < 0.05 compared with the corresponding mean of patients from group A (unpaired
Wilcoxon test).
FIG.  3.  Relationship  between  plasma  malondialdehyde
(MDA) and T-lymphocyte proliferation in the cystic fibrosis
patients. The association were analyzed using the Spearmen
rank correlation (R = 0.61, P = 0.01).
FIG. 4. Peripheral blood lymphocyte susceptibility to steroid
suppression. Inhibition degree of PHA-induced lymphocyte
proliferation by different concentrations of dexamethasone
was evaluated. The cell sensitivity is presented as the mean
of  the  D h value  (P1,2 =  0.068,  P3,4 =  0.030,  two-sample
Wilcoxon test; P1,3 = 0.035, unpaired Wilcoxon test).decrease  elevated  values  of  in  situ inflammatory
markers.  In  both  patient  groups,  all  indexes  of
inflammation were situated within the same range as
at the exacerbation period.
Discussion
CF patients are regularly exposed to increased oxida-
tive  stress,  which  appears to  be  a consequence  of
chronic pulmonary inflammation rather then part of
the primary cystic fibrosis defect.21 Due to chronic
basal free radical attack, their exhausted antioxidant
defenses are unable to recover in the spaces between
exacerbations.22 In  addition, deficiency of  systemic
scavengers may be aggravated by malabsorption of fat-
soluble antioxidants secondary to pancreatic insuffi-
ciency.  ROS  produced  by  activated phagocytes are
important in the killing of pathogens, but may damage
host tissues attacking structural phospholipids, pro-
teins, carbohydrates and DNA.23The main lipid targets
of free radicals are the PUFAs of membrane phospho-
lipids  that  undergo  peroxidation,  resulting  in  the
formation of lipid hydroperoxides and their degrada-
tion products  such as MDA.24 Thereafter,  increased
free  radical  damage  associated  with  acute  lung
exacerbation may be reflected in the elevated plasma
MDA levels. Antibiotic treatment reduces lung inflam-
mation,  which  should  result  in  decreased  oxygen
radical production. Accordingly, for the patients from
group A, a mild reduction in plasma MDA concentra-
tions  compared  with  pretreatment  levels  has  been
observed. In contrast, plasma MDA levels in group B
did increase significantly following treatment, indicat-
ing oxidative lipid damage during clinical resolution.
This finding seems, at first, to contrast with those from
trials that consider the elevated plasma MDA level as
one of the signs of ongoing infection.22,25 However,
increased plasma MDA concentration is a consequence
of free radical damage in the circulation and cannot
reflect solely those processes occurring in bronchi.
Elevated MDA levels in group B may be interpreted
as  systemic  evidence  of  increased  oxidative  stress.
The  patients  were  started  on  the  microspheric
enzymes at a time of acute lung exacerbation when
their susceptibility to oxidative stress was markedly
increased. Adequate  enzyme  replacement  improved
nutrient absorption, which should result in elevation
of plasma PUFAs, lipoprotein and cholesterol concen-
trations. In this way, new lipid targets of free radicals
have suddenly  appeared in the circulation, and the
exhausted system of antioxidant defense was unable
to prevent their oxidation.
Improvement  in  fat  absorption  and  associated
oxidative stress might be relevant to the increase in
T-cell proliferation that occurred in group B (but not
in group A) after the treatment. Thus, accumulating
data  suggest  that  oxidants  and  pro-inflammatory
PUFAs can enhance cytokine production and effects,
thereby  contributing  to  lymphocyte  activation.13,26
The  proposal  is  also  confirmed  by  a  significant
positive  linear  association  between  the  level  of
lymphocyte proliferation and plasma MDA concentra-
tion in CF patients from group B.
There  are  a  large  number  of  other  potential
mechanisms that may regulate T-lymphocyte prolifera-
tion.  Some  of  them  relate  to  alteration  of  the
composition of membrane phosopholipids and, as a
consequence,  membrane  fluidity.  Changes in  mem-
brane fluidity may interrupt binding of cytokines to
their receptors and/or activity of G proteins.27 On the
other hand, since phosphoinositide, a  minor  mem-
brane phosopholipid, seems to be the major source of
the second messengers participating in T-cell receptor
signalling,  its deficiency due to impaired uptake of
dietary lipids  may  reduce T-cell  activation and  pro-
liferative  response.28 Anyway,  improvement  in  fat
absorption might restore appropriate membrane com-
position in CF tissues and normalize the lymphocyte
activity.
The comparison of in situ inflammatory markers
(TNF-a and IL-8 levels, neutrophil elastase activity and
protein content) did not reveal statistically significant
differences  between  the  patient  groups.  However,
each marker of airway inflammation was increased in
the sputum of children from group A compared with
patients from group B (see Table 2). It is possible that
soft inflammatory response in malnourished patients
was  related  to  poor  nutritional  status.  This  is  in
accordance  with  recent  trials  showing  the  strong
relationships between nutrient deficiency and immune
response.29,30 However, our previous study suggested
that in situ inflammatory markers in CF patients were
closely related to their P. aeruginosastatus. It has been
shown that the patients chronically colonized with P.
aeruginosa for 2 years or more exhibited increased
inflammatory parameters compared with uninfected
patients or children with short-term colonization.31
Individual analyses of P. aeruginosa status revealed
that five patients from group A (n = 11) and only two
patients from  group  B  (n =  8)  exhibited long-term
colonization with pathogens. At the same time, three
patients from group B and only one patient from group
A were without P. aeruginosa infection.
The  poor  P.  aeruginosa status  of  group  A  is
confirmed by evaluation of individual susceptibility to
glucocorticoids (the D h parameter, see Fig. 4). Rela-
tively low lymphocyte sensitivity to steroid suppres-
sion at a period of acute lung exacerbation (D h ~ 0) is
a systemic evidence of permanent airway infection in
this patient group.31 The patients of group B demon-
strated  significant  resistance  to  antiproliferative
action of glucocorticoids (D h > 0). Such resistance is
associated with the systemic inflammatory response
to acute infection and accompanied by the increase in
number of activated lymphocytes in the circulation.
Change from steroid resistance to steroid sensitivity of
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treatment shows that antibiotics are able to restrict
the  acute  infection  in  CF  lungs  and  suppress  the
systemic inflammatory response.
This study provides the evidence that acute lung
exacerbation in malnourished CF patients who had
irregularly received pancreatic enzyme supplements
is  associated  with  a  significant  alteration  in  T-cell
activity.  Antibiotic  therapy  and  adequate  enzyme
replacement improve lymphocyte function but lead
to  an  increase  in  systemic  oxidative  stress.  In  the
circumstances, an extra aggressive antioxidant course
in addition to conventional treatment can be recom-
mended. Our results also suggested that measurement
of inflammatory mediators in the sputa of CF patients
with chronic P. aeruginosa infection is not helpful for
identifying  acute  respiratory  exacerbation.  At  the
same time, the infectious inflammatory-immune proc-
ess  in  the  lung  could  be  measured  in  peripheral
blood. Thus, the assessment of individual susceptibil-
ity  to  glucocorticoids  (the  D h parameter)  may  be
useful to confirm acute lung exacerbation and mon-
itor the efficacy of antibiotic treatment.
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